Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.780 +0.180 (+2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,451,079
Open 7.540
Bid (Size) 7.730 (200)
Ask (Size) 7.770 (200)
Prev. Close 7.600
Today's Range 7.360 - 7.805
52wk Range 1.830 - 12.43
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Investors of ImmunityBio, Inc. (NASDAQ: IBRX) Seeking Recovery - Contact Kaplan Fox Before Deadline on May 26, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
News headline image
Investors of ImmunityBio, Inc. (NASDAQ: IBRX) Seeking Recovery - Contact Kaplan Fox Before Deadline on May 26, 2026
NEW YORK, NY - April 15, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX)... 
Via TheNewswire.com
Topics Lawsuit

Performance

YTD
+285.1%
+285.1%
1 Month
-5.2%
-5.2%
3 Month
+175.9%
+175.9%
6 Month
+210.0%
+210.0%
1 Year
+169.2%
+169.2%

More News

Read More
News headline image
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
From Pomerantz LLP
Via GlobeNewswire
News headline image
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ImmunityBio, Inc.
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Lowey Dannenberg Notifies ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Securities Class Action Deadline on May 26, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
Kaplan Fox Reminds ImmunityBio, Inc. (NASDAQ: IBRX) Investors of a Securities Class Action Deadline on May 26, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
IMMUNITYBIO Deadline to Lead in Securities Class Action Lawsuit is May 26, 2026 - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
News headline image
IMMUNITYBIO Deadline to Lead in Securities Class Action Lawsuit is May 26, 2026 - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline to Lead in Securities Fraud Lawsuit Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026 - Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 7.780
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 04/15/26 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 3.04B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.